<DOC>
	<DOCNO>NCT01353625</DOCNO>
	<brief_summary>The main purpose first human study CC-115 ass safety action new class experimental drug ( dual DNA-PK TOR kinase inhibitor ) patient advanced tumor unresponsive standard therapy determine appropriate dose tumor type later-stage clinical trial . The bioavailability tablet capsule formulation fast fed condition also evaluate patient .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Oral CC-115 Patients With Advanced Solid Tumors , Hematologic Malignancies .</brief_title>
	<detailed_description>Latest amendment clarify Chronic Lymophocytic Leukemia ( CLL ) include T-cell Prolymphocytic Leukemia ( T-PLL ) . Prior treatment drug target mTOR , P13K relate pathway permit .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Histologicallyconfirmed advance solid tumor , chronic lymphocytic leukemia , small lymphocytic lymphoma , Tcell prolymphocytic leukemia , NonHodgkin Lymphoma multiple myeloma Progressed tolerated standard therapy , standard therapy available Archival screen tumor biopsy Eastern Cooperative Oncology Group Performance Status : 0 1 Adequate organ function Prior cancerdirected modality investigational drug within 4 wks 5 half life , whichever short Symptomatic brain metastasis ( prior treatment stable metastasis allow ) Acute chronic renal disease pancreatitis Diarrhea ≥ Grade 2 , impair gastrointestinal absorption Impaired cardiac function History diabetes require treatment , glucose &gt; 126 mg/dL , Glycated hemoglobin ( HbA1c ) ≥6.5 % Peripheral neuropathy ≥ Grade 2 Known Human Immunodeficiency Virus ( HIV ) infection , chronic hepatitis B C ( unless associate hepatocellular cancer ) Pregnant , inadequate contraception , breast feeding Most concurrent second malignancy Part B : Prior treatment agent target mammalian target rapamycin ( mTOR ) complex ( dual mammalian target rapamycin complex 1/2 inhibitor ) and/or PI3K/AKT pathway . However , prior treatment isolate target rapamycin complex 1 ( TORC1 ) inhibitor ( eg. , rapalogs ) allow part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoplasm</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>mTOR kinase inhibitor</keyword>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Hormone-resistant prostate cancer</keyword>
	<keyword>Diffuse Large B-cell lymphoma</keyword>
</DOC>